TransUnion offloads its healthcare business to Clearlake Capital Group-backed nThrive for $1.7B

  • (NYSE:TRU) has sold TransUnion Healthcare, Inc. to Clearlake Capital Group backed nThrive, Inc. for $1.735B in cash, which will result in approximately $1.4 B in after-tax proceeds at current tax rates.
  • The transaction is expected to close in 4Q21.
  • The proceeds will be utilized to prepay debt and fund future M&A transactions that reinforce, extend and scale its core positions and which can be leveraged globally - such as the pending acquisitions of Neustar and Sontiq, both of which are expected to accelerate company's long-term revenue growth.
  • 'With the divestiture of TransUnion Healthcare, TransUnion will bring greater focus to our position as a global information and insights company providing credit, marketing and fraud mitigation solutions to help businesses and consumers transact with greater certainty," said Chris Cartwright, President and CEO of TransUnion . 'The transaction will also allow TransUnion Healthcare to benefit from ownership whose priorities and expertise are solely focused on healthcare revenue cycle management."

    Over the current book year the total revenu from the company based in Chicago will be 3.08 billion USD (consensus estimates). This is hugely more than 2021's revenue of 2.72 billion USD.

    Historical revenues and results TransUnion plus estimates 2021

    financiële analyse

    The analysts expect for 2021 a net profit of 699 million USD. For this year the consensus of the result per share is a profit of 3.75 USD. So the price/earnings-ratio equals 30.74.

    Per share the analysts expect a dividend of 37 cents per share. The dividend yield is then 0.32 percent. The average dividend yield of the health care companies equals a limited 1.27 percent.

    TransUnion 's market capitalization is based on the number of outstanding shares around 21.76 billion USD. 45

    On Friday the stock closed at 115.29 USD.

    Historical stock prices TransUnion past 10 years

    financial analysis transunion

    ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
    news@valuespectrum.com

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.